Jenny Barnett
Directeur Général chez Monument Therapeutics Ltd.
Provenance du réseau au premier degré de Jenny Barnett
Entité | Type d'entité | Industrie | |
---|---|---|---|
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jenny Barnett via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
BTG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Founder | |
University of Cambridge | College/University | Doctorate Degree | |
Cambridge Drug Discovery Holdings Ltd.
Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Miscellaneous Commercial Services | Chief Executive Officer | |
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Founder | |
University of Kentucky | College/University | Corporate Officer/Principal | |
Chroma Therapeutics Ltd.
Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Biotechnology | Director/Board Member | |
The University of Nottingham | College/University | Undergraduate Degree Doctorate Degree | |
University of St. Andrews | College/University | Undergraduate Degree | |
NeuroSolutions Ltd.
NeuroSolutions Ltd. Miscellaneous Commercial ServicesCommercial Services NeuroSolutions Ltd. provides flexible and skilled services to biopharmaceutical companies with a fast turnaround time. The private company is based in Coventry, UK. The British company has a large portfolio of clients, ranging from small start-ups to multinational pharmaceutical companies, which validates their quality, reliability, speed, and discretion. The company was founded by Kevin Lee. NeuroSolutions was acquired by NeuroSolutions /Private Group/ from OncoSil Medical Ltd. on August 11, 2010 for $0.72 million. | Miscellaneous Commercial Services | Chairman | |
ONCOSIL MEDICAL LIMITED | Medical Specialties | Chairman | |
University of Basel | College/University | Corporate Officer/Principal | |
Polpharma Biologics Utrecht BV
Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Chairman | |
VERONA PHARMA PLC | Pharmaceuticals: Major | Director of Finance/CFO | |
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Ampika Ltd.
Ampika Ltd. Drugstore ChainsRetail Trade Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom. | Drugstore Chains | Founder | |
DIUL GROUP | Pharmaceuticals: Major | Chief Executive Officer | |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | Medical/Nursing Services | Director/Board Member | |
Smith Kline & French Laboratories Ltd.
Smith Kline & French Laboratories Ltd. Pharmaceuticals: MajorHealth Technology Smith Kline & French Laboratories Ltd. manufactures pharmaceutical products. The company is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Macrotarg Ltd.
Macrotarg Ltd. BiotechnologyHealth Technology Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK. | Biotechnology | Director/Board Member | |
Nasdaq Corporate Solutions International Ltd.
Nasdaq Corporate Solutions International Ltd. Packaged SoftwareTechnology Services Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom. | Packaged Software | Director/Board Member | |
Chiroscience Ltd. | Corporate Officer/Principal | ||
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
CAMBRIDGE COGNITION HOLDINGS PLC | Packaged Software | Director/Board Member | |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Cyclofluidic Ltd.
Cyclofluidic Ltd. Miscellaneous Commercial ServicesCommercial Services Cyclofluidic Ltd. is a British private company. The firm operates proprietary microfluidic drug discovery platform. | Miscellaneous Commercial Services | Chairman | |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
MEREO BIOPHARMA GROUP PLC | Biotechnology | Director of Finance/CFO | |
ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Founder | |
Diurnal Ltd.
Diurnal Ltd. Pharmaceuticals: MajorHealth Technology Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions. | Pharmaceuticals: Major | Director/Board Member | |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Exvastat Ltd.
Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
NUFORMIX PLC | Biotechnology | Chairman | |
Pharmasum Therapeutics AS
Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Biotechnology | Director/Board Member | |
River Biomedics B V I.O.
River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper. | Medical Specialties | Chairman | |
Imophoron Ltd.
Imophoron Ltd. BiotechnologyHealth Technology Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022. | Biotechnology | Chief Executive Officer | |
Spliceor Ltd.
Spliceor Ltd. BiotechnologyHealth Technology Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow. | Biotechnology | Director/Board Member | |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | Miscellaneous Commercial Services | Chairman |
Statistiques
Internationale
Royaume-Uni | 39 |
Etats-Unis | 4 |
Pays-Bas | 3 |
France | 2 |
Australie | 2 |
Sectorielle
Health Technology | 32 |
Commercial Services | 7 |
Consumer Services | 6 |
Technology Services | 3 |
Process Industries | 2 |
Opérationnelle
Director/Board Member | 24 |
Chairman | 12 |
Corporate Officer/Principal | 10 |
Founder | 7 |
Chief Executive Officer | 6 |
Relations les plus connectées
Insiders | |
---|---|
Jonathan Treherne | 24 |
Richard Bungay | 14 |
Julian Gilbert | 14 |
- Bourse
- Insiders
- Jenny Barnett
- Connexions Sociétés